Idex Corporation (CH:ID7)
NYSE:ID7
ID7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
HST Outperformance & BacklogSustained double-digit orders and revenue growth in the Health & Science Technologies platform, plus a 100bp EBITDA margin lift and an expanding backlog, signal durable end-market demand (data centers, semiconductors, pharma). This provides multi-quarter visibility and supports above-company organic growth over time.
Strong Liquidity & Capital AllocationLarge liquidity reserves, moderate gross leverage (~2x) and disciplined buybacks plus steady dividends create financial optionality for bolt-on M&A and cyclical buffering. This capital flexibility supports long-term strategic execution and shareholder returns without materially stressing the balance sheet.
Consolidated Margin ExpansionYear-over-year EBITDA margin improvement indicates effective cost discipline and pricing power across the diversified portfolio. If sustained, these structural productivity gains and pricing actions can improve earnings resiliency through cycles and fund reinvestment or M&A without eroding returns.
Bears Say
Volatile Free Cash FlowDespite strong cash conversion in typical periods, the large TTM FCF drop signals material volatility tied to working capital or investment timing. This undermines predictability for capex, acquisitions and buybacks, raising the risk that funding patterns or returns fluctuate materially across reporting periods.
Life Sciences End-market PressureWeakness in life-science demand, especially from China and constrained public funding, can permanently pressure higher-margin product mix in HST and adjacent segments. Prolonged softness would limit margin expansion potential and slow the pace at which acquired businesses can be accretive to overall profitability.
Incremental Margin & Mix HeadwindsAcquisition-driven mix shifts and lower-margin add-ons reduce incremental flow-through, meaning revenue gains translate less efficiently into EBITDA. This structural drag requires 8020 portfolio actions to restore higher incremental margins and could delay margin targets while integration and portfolio optimization proceed.
IDEX News
ID7 FAQ
What was Idex Corporation’s price range in the past 12 months?
Currently, no data Available
What is Idex Corporation’s market cap?
Idex Corporation’s market cap is CHF12.65B.
When is Idex Corporation’s upcoming earnings report date?
Idex Corporation’s upcoming earnings report date is Jul 28, 2026 which is in 51 days.
How were Idex Corporation’s earnings last quarter?
Idex Corporation released its earnings results on Apr 29, 2026. The company reported $1.562 earnings per share for the quarter, beating the consensus estimate of $1.382 by $0.18.
Is Idex Corporation overvalued?
According to Wall Street analysts Idex Corporation’s price is currently Undervalued.
Does Idex Corporation pay dividends?
Idex Corporation does not currently pay dividends.
What is Idex Corporation’s EPS estimate?
Idex Corporation’s EPS estimate is 1.65.
How many shares outstanding does Idex Corporation have?
Currently, no data Available
What happened to Idex Corporation’s price movement after its last earnings report?
Idex Corporation reported an EPS of $1.562 in its last earnings report, beating expectations of $1.382. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Idex Corporation?
Currently, no hedge funds are holding shares in CH:ID7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF190.92 (― Downside)
CHF190.92 (― Downside)
Insider Transactions
Sold Shares
Worth CHF2.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.29%
12-Months-Change
Fundamentals
Return on Equity
12.61%
Trailing 12-Months
Asset Growth
1.82%
Trailing 12-Months
Company Description
Idex Corporation
IDEX Corporation, together with its subsidiaries, provides applied solutions worldwide. The company operates through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT segment designs, produces, and distributes positive displacement pumps, small volume provers, flow meters, injectors, and other fluid-handling pump modules and systems, as well as offers flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural, and energy industries. The HST segment designs, produces, and distributes precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, laboratory and commercial equipment, precision photonic solutions, and precision gear and peristaltic pump technologies. This segment serves food and beverage, pharmaceutical and biopharmaceutical, cosmetics, marine, chemical, wastewater and water treatment, life sciences, research, and defense markets. The FSDP segment designs, produces, and distributes firefighting pumps, valves and controls, rescue tools, lifting bags, and other components and systems for the fire and rescue industry; engineered stainless steel banding and clamping devices for various industrial and commercial applications; and precision equipment for dispensing, metering, and mixing colorants and paints used in retail and commercial businesses. IDEX Corporation was incorporated in 1987 and is headquartered in Northbrook, Illinois.
ID7 Company Deck
ID7 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call skewed positive: management reported better-than-expected Q1 results, raised full-year organic growth and EPS guidance, highlighted strong HST order and revenue momentum with meaningful backlog and margin expansion, maintained aggressive share repurchases and an active bolt-on M&A pipeline, and ended the quarter with strong liquidity. Offsetting items include mixed short-cycle industrial performance, pressure in life sciences and some gross margin/mix headwinds; free cash flow was modestly lower in the seasonally weak quarter. On balance, the positive operational progress, upgraded guidance and financial optionality outweigh the contained challenges.View all CH:ID7 earnings summariesID7 Net sales Breakdown
35.36% Fluid & Metering Technologies
43.11% Health & Science Technologies
21.53% Fire & Safety/Diversified Products
ID7 Stock 12 Month Forecast
Average Price Target
$190.92
Options Prices
Currently, No data available
---